NuCana Shares Plunge Despite Positive Clinical Trial Data

Market Sells Off on Seemingly Good News

NuCana plc witnessed dramatic trading activity on Wednesday, with its shares swinging by more than 15% before ultimately closing nearly 9% lower. This sharp decline occurred despite the release of encouraging clinical results for the company’s flagship drug candidate, NUC-3373, leaving market observers puzzled by the negative investor response.

The data released on October 14 from the NuTide:303 study appeared fundamentally positive. The research demonstrated significant tumor reduction in heavily pre-treated patients suffering from advanced solid tumors. Furthermore, the combination of NUC-3373 with the PD-1 inhibitor Pembrolizumab exhibited not only promising efficacy but also a favorable safety profile. Contrary to expectations, this news triggered a sell-off, driving the share price down from $5.85 to $5.36—a loss of 8.38%.